Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Poziotinib in NSCLC with EGFR or HER2 Exon 20 Insertion Mutation (ZENITH20)
NCT03318939Phase 2Terminated
- Sponsor
- Spectrum Pharmaceuticals, Inc.
- Start
- Oct 2017
- Primary completion
- Apr 2023
- Modality
- Small Molecules
- Countries
- 8
01
Overview
A Phase 2 trial of poziotinib in non-small cell lung cancer (NSCLC), sponsored by Spectrum Pharmaceuticals, Inc.. Started Oct 2017; status: terminated.
02
Drugs
poziotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03318939.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03318939.